Sanofi Completes Acquisition of Blueprint Medicines

Sanofi has finalized its acquisition of Blueprint Medicines, a strategic move to enhance its portfolio with a commercialized medicine and a promising pipeline. This acquisition, announced on July 18, 2025, includes Ayvakit/Ayvakyt, the only approved treatment for advanced and indolent systemic mastocytosis (SM), and the investigational drug elenestinib.

The acquisition enhances Sanofi's presence among specialists in allergists, dermatologists, and immunologists, and aims to bolster its immunology pipeline. By integrating Blueprint's expertise, Sanofi expects to see immediate benefits to its gross margin, operating income, and earnings per share by 2026.

The transaction was financed using cash on hand and commercial paper issuances, with minimal impact on Sanofi's 2025 financial guidance.